Robert W Robey

List of Publications by Year
in descending order

113 papers	10,564 citations	34105 52 h-index	31849 101 g-index
120 all docs	120 docs citations	120 times ranked	10857 citing authors

#	Article	IF	Citations
1	Revisiting the role of ABC transporters in multidrug-resistant cancer. Nature Reviews Cancer, 2018, 18, 452-464.	28.4	1,181
2	Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Blood, 2001, 98, 2865-2868.	1.4	458
3	Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clinical Cancer Research, 2002, 8, 718-28.	7.0	410
4	ABCG2: A perspective. Advanced Drug Delivery Reviews, 2009, 61, 3-13.	13.7	409
5	Lapatinib (Tykerb, GW572016) Reverses Multidrug Resistance in Cancer Cells by Inhibiting the Activity of ATP-Binding Cassette Subfamily B Member 1 and G Member 2. Cancer Research, 2008, 68, 7905-7914.	0.9	362
6	ABCG2: determining its relevance in clinical drug resistance. Cancer and Metastasis Reviews, 2007, 26, 39-57.	5.9	350
7	Pheophorbide a Is a Specific Probe for ABCG2 Function and Inhibition. Cancer Research, 2004, 64, 1242-1246.	0.9	331
8	Erlotinib (Tarceva, OSI-774) Antagonizes ATP-Binding Cassette Subfamily B Member 1 and ATP-Binding Cassette Subfamily G Member 2â€“Mediated Drug Resistance. Cancer Research, 2007, 67, 11012-11020.	0.9	280
9	Transport of methotrexate, methotrexate polyglutamates, and 17beta-estradiol 17-(beta-D-glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transport. Cancer Research, 2003, 63, 4048-54.	0.9	245
10	Single nucleotide polymorphisms modify the transporter activity of ABCG2. Cancer Chemotherapy and Pharmacology, 2005, 56, 161-172.	2.3	217
11	A functional assay for detection of the mitoxantrone resistance protein, MXR (ABCG2). Biochimica Et Biophysica Acta - Biomembranes, 2001, 1512, 171-182.	2.6	216
12	Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors. Expert Review of Anticancer Therapy, 2010, 10, 997-1008.	2.4	215
13	Sunitinib (Sutent, SU11248), a Small-Molecule Receptor Tyrosine Kinase Inhibitor, Blocks Function of the ATP-Binding Cassette (ABC) Transporters P-Glycoprotein (ABCB1) and ABCG2. Drug Metabolism and Disposition, 2009, 37, 359-365.	3.3	209
14	Comparison of ATP-Binding Cassette Transporter Interactions with the Tyrosine Kinase Inhibitors Imatinib, Nilotinib, and Dasatinib. Drug Metabolism and Disposition, 2010, 38, 1371-1380.	3.3	202
15	T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance. Blood, 2004, 103, 4636-4643.	1.4	188
16	Overexpression of wild-type breast cancer resistance protein mediates methotrexate resistance. Cancer Research, 2002, 62, 5035-40.	0.9	188
17	The controversial role of ABC transporters in clinical oncology. Essays in Biochemistry, 2011, 50, 209-232.	4.7	185
18	ABCG2: structure, function and role in drug response. Expert Opinion on Drug Metabolism and Toxicology, 2008, 4, 1-15.	3.3	182

#	Article	IF	Citations
19	Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients. Cancer Biology and Therapy, 2007, 6, 432-438.	3.4	177
20	ABCG2-mediated transport of photosensitizers: Potential impact on photodynamic therapy. Cancer Biology and Therapy, 2005, 4, 195-202.	3.4	175
21	Sildenafil Reverses ABCB1- and ABCG2-Mediated Chemotherapeutic Drug Resistance. Cancer Research, 2011, 71, 3029-3041.	0.9	157
22	A Pharmacodynamic Study of Docetaxel in Combination with the P-glycoprotein Antagonist Tariquidar (XR9576) in Patients with Lung, Ovarian, and Cervical Cancer. Clinical Cancer Research, 2011, 17, 569-580.	7.0	149
23	Low Concentrations of the Histone Deacetylase Inhibitor, Depsipeptide (FR901228), Increase Expression of the Na⁺/I^{â^'}Symporter and Iodine Accumulation in Poorly Differentiated Thyroid Carcinoma Cells. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 3430-3435.	3.6	144
24	Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1Â®. Biochemical Pharmacology, 2008, 75, 1302-1312.	4.4	143
25	A High-Throughput Cell-Based Assay for Inhibitors of ABCG2 Activity. Journal of Biomolecular Screening, 2006, 11, 176-183.	2.6	128
26	A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma. Cancer, 2002, 94, 2333-2343.	4.1	119
27	Histone Deacetylase Inhibitors: Emerging Mechanisms of Resistance. Molecular Pharmaceutics, 2011, 8, 2021-2031.	4.6	110
28	Single-Nucleotide Polymorphism (SNP) Analysis in the ABC Half-Transporter ABCG2 (MXR/BCRP/ABCP1). Cancer Biology and Therapy, 2002, 1, 696-702.	3.4	109
29	Escape from hsa-miR-519c enables drug-resistant cells to maintain high expression of ABCG2. Molecular Cancer Therapeutics, 2009, 8, 2959-2968.	4.1	107
30	Inhibitors of Histone Deacetylases Alter Kinetochore Assembly by Disrupting Pericentromeric Heterochromatin. Cell Cycle, 2005, 4, 717-726.	2.6	105
31	Side Population Analysis Using a Violet-Excited Cell-Permeable DNA Binding Dye. Stem Cells, 2007, 25, 1029-1036.	3.2	101
32	A Phase I Study of the P-Glycoprotein Antagonist Tariquidar in Combination with Vinorelbine. Clinical Cancer Research, 2009, 15, 3574-3582.	7.0	101
33	Increased MDR1 Expression in Normal and Malignant Peripheral Blood Mononuclear Cells Obtained from Patients Receiving Depsipeptide (FR901228, FK228, NSC630176). Clinical Cancer Research, 2006, 12, 1547-1555.	7.0	97
34	Mutational Analysis of ABCG2:â€‰ Role of the GXXXG Motif. Biochemistry, 2004, 43, 9448-9456.	2.5	96
35	Phase I Study of Infusional Paclitaxel in Combination With the P-Glycoprotein Antagonist PSC 833. Journal of Clinical Oncology, 2001, 19, 832-842.	1.6	95
36	The Calcium Channel Blockers, 1,4-Dihydropyridines, Are Substrates of the Multidrug Resistance-Linked ABC Drug Transporter, ABCG2. Biochemistry, 2006, 45, 8940-8951.	2.5	91

#	Article	IF	Citations
37	Proteasome inhibitors increase tubulin polymerization and stabilization in tissue culture cells: A possible mechanism contributing to peripheral neuropathy and cellular toxicity following proteasome inhibition. Cell Cycle, 2008, 7, 940-949.	2.6	91
38	Reduced drug accumulation and multidrug resistance in human breast cancer cells without associated P-glycoprotein or MRP overexpression. Journal of Cellular Biochemistry, 1997, 65, 513-526.	2.6	87
39	ABC Transporters: Unvalidated Therapeutic Targets in Cancer and the CNS. Anti-Cancer Agents in Medicinal Chemistry, 2010, 10, 625-633.	1.7	82
40	ABCG2 Mediates Differential Resistance to SN-38 (7-Ethyl-10-hydroxycamptothecin) and Homocamptothecins. Journal of Pharmacology and Experimental Therapeutics, 2004, 310, 836-842.	2.5	81
41	Mitochondrial ATP fuels ABC transporter-mediated drug efflux in cancer chemoresistance. Nature Communications, 2021, 12, 2804.	12.8	77
42	Flow cytometric analysis of breast cancer resistance protein expression and function. Cytometry, 2002, 48, 59-65.	1.8	75
43	Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral Tâ€cell lymphoma. British Journal of Haematology, 2010, 148, 256-267.	2.5	74
44	A Phase I/II Study of Infusional Vinblastine with the P-Glycoprotein Antagonist Valspodar (PSC 833) in Renal Cell Carcinoma. Clinical Cancer Research, 2004, 10, 4724-4733.	7.0	69
45	Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478. Biochemical Pharmacology, 2009, 77, 781-793.	4.4	69
46	MAPK pathway activation leads to Bim loss and histone deacetylase inhibitor resistance: rationale to combine romidepsin with an MEK inhibitor. Blood, 2013, 121, 4115-4125.	1.4	69
47	The Challenge of Exploiting ABCG2 in the Clinic. Current Pharmaceutical Biotechnology, 2011, 12, 595-608.	1.6	66
48	ABCG2-mediated transport of photosensitizers: potential impact on photodynamic therapy. Cancer Biology and Therapy, 2005, 4, 187-94.	3.4	65
49	ABCG2 Harboring the Gly482 Mutation Confers High-Level Resistance to Various Hydrophilic Antifolates. Cancer Research, 2005, 65, 8414-8422.	0.9	57
50	Inhibition of ABCG2-mediated transport by protein kinase inhibitors with a bisindolylmaleimide or indolocarbazole structure. Molecular Cancer Therapeutics, 2007, 6, 1877-1885.	4.1	57
51	New inhibitors of ABCG2 identified by high-throughput screening. Molecular Cancer Therapeutics, 2007, 6, 3271-3278.	4.1	57
52	P-Glycoproteinâ€"a Clinical Target in Drug-Refractory Epilepsy?. Molecular Pharmacology, 2008, 73, 1343-1346.	2.3	54
53	Accompanying protein alterations in malignant cells with a microtubule-polymerizing drug-resistance phenotype and a primary resistance mechanism 1 1Abbreviations: MTs, microtubules; MAPs, microtubule-associated proteins; MAP4, microtubule-associated protein-4; PTX, paclitaxel; EPOA, epothilone A; EPOB, epothilone B; EPOA-R, epothilone A-resistant; COL, colchicine; VCR, vincristine; and VBL, vinblastine.. Biochemical Pharmacology, 2001, 62, 1469-1480.	4.4	53
54	Model systems for studying the blood-brain barrier: Applications and challenges. Biomaterials, 2019, 214, 119217.	11.4	50

#	Article	IF	Citations
55	Botryllamides: Natural Product Inhibitors of ABCG2. ACS Chemical Biology, 2009, 4, 637-647.	3.4	49
56	Characterization of Gene Rearrangements Leading to Activation of MDR-1*. Journal of Biological Chemistry, 2006, 281, 36501-36509.	3.4	48
57	Histone Deacetylase Inhibitors Influence Chemotherapy Transport by Modulating Expression and Trafficking of a Common Polymorphic Variant of the ABCG2 Efflux Transporter. Cancer Research, 2012, 72, 3642-3651.	0.9	42
58	Overlapping Substrate and Inhibitor Specificity of Human and Murine ABCG2. Drug Metabolism and Disposition, 2013, 41, 1805-1812.	3.3	42
59	The epidermal growth factor tyrosine kinase inhibitor AG1478 and erlotinib reverse ABCG2-mediated drug resistance. Oncology Reports, 2009, 21, 483-9.	2.6	42
60	Icotinib antagonizes ABCG2-mediated multidrug resistance, but not the pemetrexed resistance mediated by thymidylate synthase and ABCG2. Oncotarget, 2014, 5, 4529-4542.	1.8	41
61	Histone deacetylase inhibitorâ€mediated cell death is distinct from its global effect on chromatin. Molecular Oncology, 2014, 8, 1379-1392.	4.6	39
62	Porphyrin-lipid assemblies and nanovesicles overcome ABC transporter-mediated photodynamic therapy resistance in cancer cells. Cancer Letters, 2019, 457, 110-118.	7.2	39
63	Mutational Analysis of Threonine 402 Adjacent to the GXXXG Dimerization Motif in Transmembrane Segment 1 of ABCG2. Biochemistry, 2010, 49, 2235-2245.	2.5	38
64	Pancreatic Cancer: â€œA Riddle Wrapped in a Mystery inside an Enigmaâ€• Clinical Cancer Research, 2017, 23, 1629-1637.	7.0	38
65	A Pharmacodynamic Study of the Pâ€glycoprotein Antagonist CBTâ€1Â® in Combination With Paclitaxel in Solid Tumors. Oncologist, 2012, 17, 512.	3.7	37
66	Mutational Studies of G553 in TM5 of ABCG2:Â A Residue Potentially Involved in Dimerizationâ€. Biochemistry, 2006, 45, 5251-5260.	2.5	36
67	Reduced Expression of DNA Topoisomerase I in SF295 Human Glioblastoma Cells Selected for Resistance to Homocamptothecin and Diflomotecan. Molecular Pharmacology, 2008, 73, 490-497.	2.3	36
68	FR901228 causes mitotic arrest but does not alter microtubule polymerization. Anti-Cancer Drugs, 2000, 11, 445-454.	1.4	35
69	Histone deacetylase inhibitor FR901228 enhances adenovirus infection of hematopoietic cells. Blood, 2002, 99, 2248-2251.	1.4	34
70	Rapid detection of ABC transporter interaction: Potential utility in pharmacology. Journal of Pharmacological and Toxicological Methods, 2011, 63, 217-222.	0.7	34
71	A thalidomide analogue with in vitro antiproliferative, antimitotic, and microtubule-stabilizing activities. Molecular Cancer Therapeutics, 2006, 5, 450-456.	4.1	33
72	Clinical Reversal of Multidrug Resistance. Stem Cells, 1996, 14, 56-63.	3.2	31

#	Article	IF	Citations
73	Characterization of ABCG2 gene amplification manifesting as extrachromosomal DNA in mitoxantrone-selected SF295 human glioblastoma cells. Cancer Genetics and Cytogenetics, 2005, 160, 126-133.	1.0	31
74	Linsitinib (OSI-906) antagonizes ATP-binding cassette subfamily G member 2 and subfamily C member 10-mediated drug resistance. International Journal of Biochemistry and Cell Biology, 2014, 51, 111-119.	2.8	29
75	Differential Gene and MicroRNA Expression between Etoposide Resistant and Etoposide Sensitive MCF7 Breast Cancer Cell Lines. PLoS ONE, 2012, 7, e45268.	2.5	27
76	Identification of Compounds that Correlate with ABCG2 Transporter Function in the National Cancer Institute Anticancer Drug Screen. Molecular Pharmacology, 2009, 76, 946-956.	2.3	26
77	Arginine 383 is a crucial residue in ABCG2 biogenesis. Biochimica Et Biophysica Acta - Biomembranes, 2009, 1788, 1434-1443.	2.6	26
78	A role for ceramide glycosylation in resistance to oxaliplatin in colorectal cancer. Experimental Cell Research, 2020, 388, 111860.	2.6	26
79	Becatecarin (rebeccamycin analog, NSC 655649) is a transport substrate and induces expression of the ATP-binding cassette transporter, ABCG2, in lung carcinoma cells. Cancer Chemotherapy and Pharmacology, 2009, 64, 575-583.	2.3	25
80	Multidrug transporters: recent insights from cryo-electron microscopy-derived atomic structures and animal models. F1000Research, 2020, 9, 17.	1.6	25
81	Evidence for Microtubule Target Engagement in Tumors of Patients Receiving Ixabepilone. Clinical Cancer Research, 2007, 13, 7480-7486.	7.0	24
82	Loss of the proteins Bak and Bax prevents apoptosis mediated by histone deacetylase inhibitors. Cell Cycle, 2013, 12, 2829-2838.	2.6	24
83	Association of the ABCG2 C421A polymorphism with prostate cancer risk and survival. BJU International, 2008, 102, 1694-1699.	2.5	22
84	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Molecular Pharmacology, 2019, 96, 629-640.	2.3	22
85	The livestock photosensitizer, phytoporphyrin (phylloerythrin), is a substrate of the ATP-binding cassette transporter ABCG2. Research in Veterinary Science, 2006, 81, 345-349.	1.9	20
86	Assessment of Drug Transporter Function Using Fluorescent Cell Imaging. Current Protocols in Toxicology / Editorial Board, Mahin D Maines (editor-in-chief) [et Al], 2013, 57, Unit 23.6..	1.1	19
87	Spatial control of oxygen delivery to threeâ€dimensional cultures alters cancer cell growth and gene expression. Journal of Cellular Physiology, 2019, 234, 20608-20622.	4.1	17
88	Coexpression of ABCB1 and ABCG2 in a Cell Line Model Reveals Both Independent and Additive Transporter Function. Drug Metabolism and Disposition, 2019, 47, 715-723.	3.3	17
89	Histone deacetylase inhibitors induce CXCR4 mRNA but antagonize CXCR4 migration. Cancer Biology and Therapy, 2013, 14, 175-183.	3.4	15
90	Targeting mitochondrial hexokinases increases efficacy of histone deacetylase inhibitors in solid tumor models. Experimental Cell Research, 2019, 375, 106-112.	2.6	15

#	Article	IF	Citations
91	Characterization and tissue localization of zebrafish homologs of the human ABCB1 multidrug transporter. Scientific Reports, 2021, 11, 24150.	3.3	15
92	ABCG2 is expressed in late spermatogenesis and is associated with the acrosome. Biochemical and Biophysical Research Communications, 2009, 378, 302-307.	2.1	14
93	Leptin Signaling Affects Survival and Chemoresistance of Estrogen Receptor Negative Breast Cancer. International Journal of Molecular Sciences, 2020, 21, 3794.	4.1	14
94	Blocking downstream signaling pathways in the context of HDAC inhibition promotes apoptosis preferentially in cells harboring mutant Ras. Oncotarget, 2016, 7, 69804-69815.	1.8	14
95	Retained platinum uptake and indifference to p53 status make novel transplatinum agents active in platinum-resistant cells compared to cisplatin and oxaliplatin. Cell Cycle, 2012, 11, 963-973.	2.6	13
96	HG-829 Is a Potent Noncompetitive Inhibitor of the ATP-Binding Cassette Multidrug Resistance Transporter ABCB1. Cancer Research, 2012, 72, 4204-4213.	0.9	12
97	The ABCG2 Multidrug Transporter. , 2016, , 195-226.		12
98	Bax/Tubulin/Epithelial-Mesenchymal Pathways Determine the Efficacy of Silybin Analog HM015k in Colorectal Cancer Cell Growth and Metastasis. Frontiers in Pharmacology, 2018, 9, 520.	3.5	12
99	R-Loopâ€“Mediated ssDNA Breaks Accumulate Following Short-Term Exposure to the HDAC Inhibitor Romidepsin. Molecular Cancer Research, 2021, 19, 1361-1374.	3.4	12
100	In vitro and In vivo Clinical Pharmacology of Dimethyl Benzoylphenylurea, a Novel Oral Tubulin-Interactive Agent. Clinical Cancer Research, 2005, 11, 8503-8511.	7.0	10
101	Cross-resistance of cisplatin selected cells to anti-microtubule agents: Role of general survival mechanisms. Translational Oncology, 2021, 14, 100917.	3.7	8
102	CCR 20th Anniversary Commentary: Expanding the Epigenetic Therapeutic Portfolio. Clinical Cancer Research, 2015, 21, 2195-2197.	7.0	6
103	Multidrug Resistance Mediated by MDR-ABC Transporters. , 2009, , 1-20.		5
104	Clinical Reversal of Multidrug Resistance. Oncologist, 1996, 1, 269-275.	3.7	5
105	The 315â€“316 deletion determines the BXP-21 antibody epitope but has no effect on the function of wild type ABCG2 or the Q141K variant. Molecular and Cellular Biochemistry, 2009, 322, 63-71.	3.1	4
106	Mycoplasma Infection Mediates Sensitivity of Multidrug-Resistant Cell Lines to Tiopronin: A Cautionary Tale. Journal of Medicinal Chemistry, 2020, 63, 1434-1439.	6.4	4
107	Dual Inhibition of Histone Deacetylases and the Mechanistic Target of Rapamycin Promotes Apoptosis in Cell Line Models of Uveal Melanoma. , 2021, 62, 16.		4
108	A new porphyrin as selective substrate-based inhibitor of breast cancer resistance protein (BCRP/ABCG2). Chemico-Biological Interactions, 2022, 351, 109718.	4.0	4

#	Article	IF	Citations
109	ATP-binding cassette transporters at the zebrafish blood-brain barrier and the potential utility of the zebrafish as an in vivo model. , 2021, 4, 620-633.		3
110	A Histone Deacetylase Inhibitor Induces Acetyl-CoA Depletion Leading to Lethal Metabolic Stress in RAS-Pathway Activated Cells. Cancers, 2022, 14, 2643.	3.7	2
111	A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma. Cancer, 2002, 94, 2333-2343.	4.1	1
112	New and Revised Concepts in Multidrug Resistance. , 2006, , 261-282.		1
113	Inside Cover Image, Volume 234, Number 11, November 2019. Journal of Cellular Physiology, 2019, 234, ii.	4.1	0